ValuEngine upgraded shares of Kindred Biosciences (NASDAQ:KIN) from a sell rating to a hold rating in a report released on Friday.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research upgraded Kindred Biosciences from a hold rating to a buy rating and set a $8.50 price objective on the stock in a research report on Wednesday, September 6th. B. Riley restated a buy rating and set a $11.00 price objective on shares of Kindred Biosciences in a research report on Monday, November 20th. Finally, HC Wainwright initiated coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a buy rating and a $9.50 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $9.54.
Shares of Kindred Biosciences (KIN) opened at $7.50 on Friday. Kindred Biosciences has a 52-week low of $3.90 and a 52-week high of $9.65.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in Kindred Biosciences by 2.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,369,688 shares of the biopharmaceutical company’s stock worth $9,656,000 after buying an additional 34,735 shares during the period. Vanguard Group Inc. lifted its stake in shares of Kindred Biosciences by 57.7% in the 2nd quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after purchasing an additional 272,612 shares during the period. General American Investors Co. Inc. acquired a new position in shares of Kindred Biosciences in the 3rd quarter valued at about $5,232,000. Renaissance Technologies LLC lifted its stake in shares of Kindred Biosciences by 43.6% in the 1st quarter. Renaissance Technologies LLC now owns 504,800 shares of the biopharmaceutical company’s stock valued at $3,559,000 after purchasing an additional 153,200 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Kindred Biosciences by 2.2% in the 3rd quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after purchasing an additional 7,206 shares during the period. 66.85% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/05/kindred-biosciences-kin-upgraded-at-valuengine.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Kindred Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kindred Biosciences Inc and related companies.